• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Axsome Therapeutics Inc.

    4/25/25 4:32:39 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AXSM alert in real time by email
    DEFA14A 1 axsm_2025_april_proxy_-_.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934 (Amendment No.)

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under §240.14a-12

     

    AXSOME THERAPEUTICS, INC.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box):

     

    ☒

    No fee required.

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     


     

    img242522476_0.jpg

     

    Logo axsome therapeutics, inc. One world trade center, 29th floor new york, ny 10007 your vote counts! Axsome therapeutics, inc. 2025 annual meeting vote by june 5, 2025 11:59 pm et v69578-p30802 you invested in axsome therapeutics, inc. And it’s time to vote! You have the right to vote on proposals being presented at the annual meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on june 6, 2025. Get informed before you vote view the notice, proxy statement and annual report online or you can receive a free paper or email copy of the material(s) by requesting prior to may 23, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.proxyvote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.proxyvote.com control # smartphone users point your camera here and vote without entering a control number vote virtually at the meeting* june 6, 2025 9:00 am edt virtually at: www.virtualshareholdermeeting.com/axsm2025 *please check the meeting materials for any special requirements for meeting attendance.


     

    img242522476_1.jpg

     

    Vote at www.proxyvote.com this is not a votable ballot this is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Voting items board recommends 1. Election of director nominee: 01) roger jeffs, ph.d. 2. To approve the company’s 2025 long-term incentive plan. 3. To ratify the appointment of deloitte & touche llp as the company’s independent registered public accounting firm for the year ending december 31, 2025. 4. To approve, by non-binding advisory vote, the compensation of our named executive officers. Note: such other business as may properly come before the meeting or any adjournment thereof. For for for for Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V69579-P30802


    Get the next $AXSM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AXSM

    DatePrice TargetRatingAnalyst
    10/1/2025$179.00Buy
    B. Riley Securities
    9/3/2025$163.00Overweight
    Wells Fargo
    7/3/2025$190.00Overweight
    Morgan Stanley
    6/3/2025$185.00Outperform
    Oppenheimer
    4/7/2025$200.00Buy
    Jefferies
    2/11/2025$176.00Buy
    Deutsche Bank
    12/31/2024$124.00 → $122.00Outperform
    Mizuho
    9/3/2024$140.00Overweight
    Wells Fargo
    More analyst ratings

    $AXSM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Axsome Therapeutics to Participate in Upcoming Investor Conferences

    NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in December: Piper Sandler 37th Annual Healthcare Conference Fireside Chat: Wednesday, December 3, 2025, at 4:00 p.m. ET in New York, NY BofA Securities CNS Therapeutics Virtual Conference 2025 Fireside Chat: Monday, December 8, 2025, at 11:40 a.m. ET A live webcast of the presentation at the Piper Sandler conference can be accessed on the "Webcasts & Presentations" page of the "Investors" section of the Compan

    11/20/25 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

    Total 3Q 2025 net product revenue of $171.0 million, representing 63% year-over-year growth AUVELITY® 3Q 2025 net product sales of $136.1 million, representing 69% year-over-year growth SUNOSI® 3Q 2025 net product revenue of $32.8 million, representing 35% year-over-year growth SYMBRAVO® 3Q 2025 net product sales of $2.1 million sNDA for AXS-05 in Alzheimer's disease agitation submitted to the FDA Company to host conference call today at 8:00 AM Eastern NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the t

    11/3/25 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics to Participate in Upcoming Investor Conferences

    NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in November: 2025 Truist Securities BioPharma Symposium Fireside Chat: Thursday, November 6, 2025, at 9:50 a.m. ET in New York, NY Guggenheim 2nd Annual Healthcare Innovation ConferenceFireside Chat: Monday, November 10, 2025, at 11:00 a.m. ET in Boston, MA 2025 UBS Global Healthcare ConferenceFireside Chat: Tuesday, November 11, 2025, at 2:00 p.m. ET in Palm Beach Gardens, FL Live webcasts of the presentations

    10/22/25 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    SEC Filings

    View All

    SEC Form 144 filed by Axsome Therapeutics Inc.

    144 - Axsome Therapeutics, Inc. (0001579428) (Subject)

    12/4/25 5:11:24 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Axsome Therapeutics Inc.

    144 - Axsome Therapeutics, Inc. (0001579428) (Subject)

    12/3/25 5:58:16 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Axsome Therapeutics Inc.

    144 - Axsome Therapeutics, Inc. (0001579428) (Subject)

    12/2/25 5:14:05 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for AUVELITY issued to AXSOME THERAPEUTICS, INC.

    Submission status for AXSOME THERAPEUTICS, INC.'s drug AUVELITY (ORIG-1) with active ingredient DEXTROMETHORPHAN HYDROBROMIDE AND BUPROPION HYDROCHLORIDE has changed to 'Approval' on 08/18/2022. Application Category: NDA, Application Number: 215430, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    8/19/22 12:36:14 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Axsome Therapeutics with a new price target

    B. Riley Securities initiated coverage of Axsome Therapeutics with a rating of Buy and set a new price target of $179.00

    10/1/25 8:44:08 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo resumed coverage on Axsome Therapeutics with a new price target

    Wells Fargo resumed coverage of Axsome Therapeutics with a rating of Overweight and set a new price target of $163.00

    9/3/25 8:28:49 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley resumed coverage on Axsome Therapeutics with a new price target

    Morgan Stanley resumed coverage of Axsome Therapeutics with a rating of Overweight and set a new price target of $190.00

    7/3/25 7:49:15 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $AXSM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Tabuteau Herriot sold $11,648,582 worth of shares (79,973 units at $145.66) and exercised 79,973 shares at a strike of $8.02 (SEC Form 4)

    4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

    12/4/25 7:39:43 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Tabuteau Herriot exercised 163,939 shares at a strike of $8.02 and sold $21,815,669 worth of shares (163,939 units at $133.07) (SEC Form 4)

    4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

    11/5/25 7:01:02 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Tabuteau Herriot exercised 45,384 shares at a strike of $8.02 and sold $5,418,060 worth of shares (45,384 units at $119.38) (SEC Form 4)

    4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

    10/8/25 9:08:08 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Coleman Mark bought $200,466 worth of shares (1,575 units at $127.28), increasing direct ownership by 3% to 48,212 units (SEC Form 4)

    4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

    9/9/25 8:11:58 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    Financials

    Live finance-specific insights

    View All

    Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

    Total 3Q 2025 net product revenue of $171.0 million, representing 63% year-over-year growth AUVELITY® 3Q 2025 net product sales of $136.1 million, representing 69% year-over-year growth SUNOSI® 3Q 2025 net product revenue of $32.8 million, representing 35% year-over-year growth SYMBRAVO® 3Q 2025 net product sales of $2.1 million sNDA for AXS-05 in Alzheimer's disease agitation submitted to the FDA Company to host conference call today at 8:00 AM Eastern NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the t

    11/3/25 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3

    NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the third quarter of 2025 on Monday, November 3, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the "Webcasts & Presenta

    10/7/25 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

    Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY® 2Q 2025 net product sales of $119.6 million, representing growth of 84% year-over-year and 24% sequentially SUNOSI® 2Q 2025 net product revenue of $30.0 million, representing growth of 35% year-over-year and 19% sequentially SYMBRAVO® launched June 10th, with 2Q 2025 net product sales of $0.4 million AUVELITY® market access expanded by 28 million new covered lives in the commercial channel First group purchasing organization (GPO) contract for SYMBRAVO® signed Supplemental NDA submission for AXS-05 in Alzheimer's disease agit

    8/4/25 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

    SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

    2/14/24 3:46:49 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

    SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

    2/14/24 7:26:39 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

    SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

    2/13/24 4:58:57 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    Leadership Updates

    Live Leadership Updates

    View All

    Axsome Therapeutics, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 7, 2023 deadline.

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ:AXSM) investors that a lawsuit filed on behalf of investors that purchased Axsome securities between May 10, 2021 and April 22, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo

    11/28/23 6:51:20 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors

    NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Susan Mahony, PhD, has been appointed to Axsome's board of directors, effective immediately. Dr. Mahony most recently served on the board of directors of Horizon Therapeutics from 2019 until its acquisition by Amgen in October 2023. She was formerly Senior Vice President of Eli Lilly and Company and President of Lilly Oncology, where under her leadership, the business unit evolved from one to five marketed medicines. At Lilly, she held leadership position

    10/11/23 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care